Stock BGLC BIONEXUS GENE LAB CORP.
Add to a list
To use this feature you must be a member
Log inSign up

Financials BioNexus Gene Lab Corp.

Equities

BGLC

US0906282076

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 02:00:01 04/05/2024 am IST 		5-day change 1st Jan Change
0.604 USD -0.92% Intraday chart for BioNexus Gene Lab Corp. +1.77% +13.96%
16/04 BioNexus Gene Lab Corp. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
29/02 BioNexus Gene Lab Corp. Provides Information to Shareholders CI

Valuation

Fiscal Period: December 2020 2021 2022 2023
Capitalization 1 236.3 364.7 165 9.364
Enterprise Value (EV) 1 233.6 362.6 163 3.581
P/E ratio 216 x 485 x -461 x -3.2 x
Yield - - - -
Capitalization / Revenue 20.7 x 27.3 x 15.1 x 0.96 x
EV / Revenue 20.5 x 27.1 x 14.9 x 0.37 x
EV / EBITDA 355 x 316 x -816 x -1.83 x
EV / FCF -127 x -3,300 x 239 x 6.32 x
FCF Yield -0.79% -0.03% 0.42% 15.8%
Price to Book 59.1 x 50.8 x 24.8 x 0.97 x
Nbr of stocks (in thousands) 8,561 14,268 14,477 17,668
Reference price 2 27.60 25.56 11.40 0.5300
Announcement Date 30/03/21 06/04/22 31/03/23 16/04/24
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 0.2123 0.127 11.39 13.36 10.93 9.771
EBITDA 1 -0.1708 -0.234 0.6577 1.147 -0.1998 -1.959
EBIT 1 -0.2114 -0.2757 0.5669 1.056 -0.2912 -2.042
Operating Margin -99.55% -217.17% 4.98% 7.9% -2.66% -20.9%
Earnings before Tax (EBT) 1 0.0599 -0.2757 1.263 1.043 -0.3037 -2.608
Net income 1 0.0265 -0.2465 1.094 0.7516 -0.356 -2.629
Net margin 12.46% -194.14% 9.61% 5.62% -3.26% -26.91%
EPS 2 0.004818 -0.0342 0.1276 0.0527 -0.0247 -0.1656
Free Cash Flow 1 -1.129 -0.1415 -1.839 -0.1099 0.6827 0.5668
FCF margin -531.82% -111.46% -16.14% -0.82% 6.25% 5.8%
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 27/03/19 31/03/20 30/03/21 06/04/22 31/03/23 16/04/24
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 - - - - - -
Net Cash position 1 1.19 0.77 2.66 2.05 2.06 5.78
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 -1.13 -0.14 -1.84 -0.11 0.68 0.57
ROE (net income / shareholders' equity) 3.27% -18.6% 28.1% 10.9% -5.14% -32.2%
ROA (Net income/ Total Assets) -9.03% -12% 6.24% 6.7% -1.99% -12.7%
Assets 1 -0.2929 2.062 17.52 11.21 17.91 20.74
Book Value Per Share 2 0.2400 0.1300 0.4700 0.5000 0.4600 0.5500
Cash Flow per Share 2 0.1100 0.0400 0.0500 0.0400 0.0400 0.1500
Capex 1 0.04 0.01 0.42 0 0.05 0.15
Capex / Sales 18.66% 10.1% 3.7% 0.02% 0.5% 1.53%
Announcement Date 27/03/19 31/03/20 30/03/21 06/04/22 31/03/23 16/04/24
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
BIONEXUS GENE LAB CORP. Stock BioNexus Gene Lab Corp.
+13.96% 10.67M
MODERNA, INC. Stock Moderna, Inc.
+25.69% 47.86B
LONZA GROUP AG Stock Lonza Group AG
+46.90% 41.42B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-3.46% 40.66B
CELLTRION, INC. Stock Celltrion, Inc.
-6.20% 28.92B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+9.17% 25.55B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-20.42% 19.27B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+0.17% 12.15B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+28.07% 12.14B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-1.24% 11.99B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. BGLC Stock
  4. Financials BioNexus Gene Lab Corp.